Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.43B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dianthus Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 7 insiders, $29.3M in total
- Insiders trading
- 7
- Net value
- −$29.3M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dianthus Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Carr Edward | CHIEF ACCOUNTING OFFICER | 0 | Sep 18, 2026 | 3 |
| Randhawa Simrat | EVP, Head of R&D | 4,000 | Sep 3, 2026 | 5 |
| Read Simon | Director | 0 | Aug 19, 2026 | 3 |
| Veness Adam M | SVP, General Counsel and Sec. | 15,000 | Aug 14, 2026 | 4 |
| McGeorge Anne | Director | 0 | Aug 11, 2026 | 2 |
| Garcia Marino | CEO AND PRESIDENT | 65,292 | Aug 7, 2026 | 5 |
| Savitz Ryan | EVP, CFO & CBO | 0 | Jul 13, 2026 | 5 |
| Kango Sujay | Director | – | May 22, 2026 | 1 |
| Lawton Alison Frances | Director | – | May 22, 2026 | 1 |
| Romano Steven J. | Director | – | May 22, 2026 | 1 |
| Soteropoulos Paula | Director | 0 | May 22, 2026 | 4 |
| Violin Jonathan | Director | – | May 22, 2026 | 1 |
| Fairmount Funds Management LLC | Director | 0Indirect | Oct 1, 2024 | 0 |
| Kiselak Tomas | Director | 0Indirect | Oct 1, 2024 | 0 |
| Moulder Leon O Jr | Director | 1,436,745Indirect | May 28, 2024 | 0 |
| Harwin Peter Evan | Director, 10% Owner | 2,762,837Indirect | Jan 24, 2024 | 0 |
| Avidity Partners Management LP | Director | 2,717,554Indirect | Jan 24, 2024 | 0 |
| Meng Lei | Director | 2,717,554Indirect | Jan 24, 2024 | 0 |
| Avidity Partners Management (GP) LLC | Director | 2,717,554Indirect | Jan 24, 2024 | 0 |
| Gregory Michael David | Director | 2,717,554Indirect | Jan 24, 2024 | 0 |
| Witzke David Roy | Director | 2,717,554Indirect | Jan 24, 2024 | 0 |
| TRV GP IV, LLC | 10% Owner | 3,058,204 | Feb 9, 2023 | 0 |
| Third Rock Ventures GP IV, L.P. | 10% Owner | 3,058,204 | Feb 9, 2023 | 0 |
| Third Rock Ventures IV, L.P. | 10% Owner | 3,058,204 | Feb 9, 2023 | 0 |
| Gardner Jason | See Remarks | 292,872 | Dec 2, 2022 | 0 |
| Beetham Thomas W. | See Remarks | 19,897 | Dec 2, 2022 | 0 |
| Mahoney Stephen F. | See Remarks | 17,264 | Dec 2, 2022 | 0 |
| Stants Kristen | Chief People Officer | 20,264 | Dec 2, 2022 | 0 |
| Deardorf Caren | Chief Commercial Officer | 19,762 | Dec 2, 2022 | 0 |
| Vasconcelles Michael | Director | – | Aug 17, 2022 | 0 |
| Humphrey Jeffrey | Chief Medical Officer | – | Aug 1, 2022 | 0 |
| Olson Lisa | See Remarks | 14,264 | Aug 1, 2022 | 0 |
| Nichols David Wayne | Chief Technical Officer | 14,306 | Aug 1, 2022 | 0 |
| Ronneberg Amy L | Director | – | Jun 30, 2022 | 0 |
| Booth Bruce | Director | – | Jun 30, 2022 | 0 |
| Daniel Thomas O | Director | – | Jun 30, 2022 | 0 |
| Albers Jeffrey W. | Director | – | Jun 30, 2022 | 0 |
| Scadden David | Director | – | Jun 30, 2022 | 0 |
| Borisy Alexis | Director | 4,100 | Sep 23, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:36 PM ET | Sep 17 | 1 day | Carr EdwardCHIEF ACCOUNTING OFFICER | SSale | −20.0K | $101.38 | −$2.03M | −100.0%0 after | 5 lots10b5-1 |
| Sep 3, 2026 (view filing)4:30 PM ET | Sep 1 | 2 days | Randhawa SimratEVP, Head of R&D | SSale | −23.1K | $106.41 | −$2.46M | −85.3%4.00K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)6:02 PM ET | Aug 19 | Same day | Read SimonDirector | SSale | −2.78K | $117.55 | −$326.6K | −100.0%0 after | 10b5-1 |
| Aug 11, 2026 (view filing)5:15 PM ET | Aug 10 | 1 day | McGeorge AnneDirector | SSale | −7.75K | $109.01 | −$844.8K | −100.0%0 after | 5 lots10b5-1 |
| Aug 11, 2026 (view filing)5:10 PM ET | Aug 10 | 1 day | Read SimonDirector | SSale | −2.78K | $109.55 | −$304.2K | −100.0%0 after | 6 lots10b5-1 |
| Aug 11, 2026 (view filing)5:08 PM ET | Aug 7-10 | 4 days | Veness Adam MSVP, General Counsel and Sec. | SSale | −20.0K | $110.44 | −$2.21M | −100.0%0 after | 3 lots10b5-1 |
| Aug 7, 2026 (view filing)6:30 PM ET | Aug 7 | Same day | Garcia MarinoCEO AND PRESIDENT | SSale | −166.0K | $108.11 | −$17.9M | −71.8%65.3K after | 7 lots10b5-1 |
| Jul 13, 2026 (view filing)5:00 PM ET | Jul 9 | 4 days | Savitz RyanEVP, CFO & CBO | SSale | −31.2K | $101.03 | −$3.16M | −100.0%0 after | 3 lots10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −30.0K | $80.80 | −$2.42M | −100.0%0 after | 2 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Randhawa SimratEVP, Head of R&D | SSale | −26.5K | $90.62 | −$2.40M | −86.9%4.00K after | 3 lots10b5-1 |
| May 11, 2026 (view filing) | May 8 | 3 days | Soteropoulos PaulaDirector | SSale | −599 | $85.47 | −$51.2K | −100.0%0 after | 10b5-1 |
| Apr 10, 2026 (view filing) | Apr 9 | 1 day | Savitz RyanEVP, CFO & CBO | SSale | −8.22K | $89.84 | −$738.8K | −100.0%0 after | 10b5-1 |
| Apr 1, 2026 (view filing) | Mar 31 | 1 day | Savitz RyanEVP, CFO & CBO | SSale | −114.4K | $83.00 | −$9.49M | −100.0%0 after | 8 lots10b5-1 |
| Apr 1, 2026 (view filing) | Mar 31 | 1 day | Soteropoulos PaulaDirector | SSale | −599 | $80.11 | −$48.0K | −100.0%0 after | 10b5-1 |
| Mar 26, 2026 (view filing) | Mar 24 | 2 days | Soteropoulos PaulaDirector | SSale | −27.6K | $78.05 | −$2.15M | −100.0%0 after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Randhawa SimratEVP, Head of R&D | SSale | −33.8K | $81.48 | −$2.76M | −100.0%0 after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Garcia MarinoCEO AND PRESIDENT | SSale | −122.9K | $81.49 | −$10.0M | −100.0%0 after | 5 lots10b5-1 |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Carr EdwardCHIEF ACCOUNTING OFFICER | SSale | −43.7K | $81.49 | −$3.56M | −100.0%0 after | 5 lots10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Savitz RyanCFO & CBO | SSale | −20.0K | $45.18 | −$903.6K | −100.0%0 after | 10b5-1 |
| Nov 14, 2025 (view filing) | Nov 13-14 | 1 day | Randhawa SimratEVP, Head of R&D | SSale | −196.5K | $37.55 | −$7.38M | −98.0%4.00K after | 4 lots10b5-1 |
| Sep 11, 2025 (view filing) | Sep 9 | 2 days | Savitz RyanCFO & CBO | SSale | −20.0K | $35.00 | −$700.0K | −100.0%0 after | 10b5-1 |
| Oct 3, 2023 (view filing)4:00 PM ET | Sep 29 | 4 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.7K | $13.63 | +$336.3K | +1.3%1.93M after | |
| Sep 28, 2023 (view filing)5:09 PM ET | Sep 26 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.15 | +$394.5K | +1.6%1.90M after | |
| Sep 25, 2023 (view filing) | Sep 21-22 | 4 days | Randhawa SimratChief Medical Officer | PPurchase | +4.00K | $13.20 | +$52.8K | New position4.00K after | 2 lots |
| Sep 21, 2023 (view filing)4:23 PM ET | Sep 19 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.20 | +$396.0K | +1.6%1.87M after | |
| Sep 13, 2023 (view filing)9:17 PM ET | Sep 12-13 | 1 day | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.3K | $11.20 | +$271.7K | +1.3%1.84M after | 2 lots |
| Feb 9, 2023 (view filing)4:30 PM ET | Feb 7-8 | 2 days | TRV GP IV, LLC and 2 others10% Owner | SSale | −3.70M | $0.8259 | −$3.06M | −54.7%3.06M after | 2 lots |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Stants KristenChief People Officer | SSale | −5.74K | $6.73 | −$38.6K | −28.7%14.3K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Mahoney Stephen F.See Remarks | SSale | −5.74K | $6.73 | −$38.6K | −28.7%14.3K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Deardorf CarenChief Commercial Officer | SSale | −6.24K | $6.73 | −$42.0K | −31.2%13.8K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Gardner JasonSee Remarks | SSale | −14.3K | $6.73 | −$96.5K | −4.8%286.9K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Beetham Thomas W.See Remarks | SSale | −6.10K | $6.73 | −$41.1K | −30.5%13.9K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Olson LisaSee Remarks | SSale | −5.74K | $6.73 | −$38.6K | −28.7%14.3K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Nichols David WayneChief Technical Officer | SSale | −5.69K | $6.73 | −$38.3K | −28.5%14.3K after |